Lilly halts UK Mounjaro orders ahead of September price rise

Eli Lilly halted shipments and stopped accepting new Mounjaro orders in the United Kingdom on Aug. 27, 2025, a temporary move made just before a price increase of as much as 170% was scheduled to begin there ^[1][2]. The company said ordering would reopen on Sept. 1 ^[1].

A Lilly spokesperson described the step as a "month-end cut off for orders" ^[2]. The company said it keeps allocations in place for pharmacies and health care providers that order directly from it, a way to manage supply and preserve patient access, and it pointed to UK legal rules meant to stop "inappropriate" stockpiling by providers ^[1][2].

"We encourage patients to only order based on their current treatment plan, to reduce the risk of localized disruption," Lilly said in its statement ^[2].

Mounjaro is the brand name used for tirzepatide in most countries outside the United States, where the drug is approved for both type 2 diabetes and obesity ^[2]. In the US, tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for obesity.

The Guardian reported that Lilly asked two British wholesalers to pause Mounjaro orders during a surge in demand, and that pharmacies had described panic buying once the higher price became known ^[2].

The numbers

The increase applies to the UK list price. According to a Financial Times report cited by Fierce Pharma, it covers private providers that negotiate their own discounts, not the National Health Service ^[2]. A month's supply at the highest dose was set to go from 122 pounds to 330 pounds, or roughly $164.81 to $445.80 at the exchange rate Reuters cited ($1 = 0.7402 pounds) ^[1].

Lilly has framed the decision as part of an effort to bring prices in line across wealthy countries, after White House pressure on manufacturers to charge more in Europe so they can charge less at home ^[1][2].

"[P]rices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said, adding that it has "intensified efforts to align prices across developed countries" ^[2].

CEO David Ricks has separately cautioned against bringing "foreign price controls" into the US market, saying that would combine "the low productivity and output of Europe's biopharma sector with the high out-of-pocket and distorted prices of the U.S. insurance market" ^[2].

How Lilly's price changes will unfold outside the UK, and whether other markets face similar supply holds, has not been reported ^[2].

Why it matters for patients

Everything described here happened in the UK market. No supply effect on US Mounjaro, Zepbound or other GLP-1 medicines has been reported.

The episode shows how a pricing decision in one country can change the way a drug moves through that country's pharmacies within days — in this case, by encouraging buyers to load up before the new price took hold and prompting a short shipping halt. For UK patients, the company's guidance was to order according to their current treatment plan rather than in advance ^[2]. Whether private UK patients end up paying the full new list price, or less through negotiated discounts, has not been disclosed in the reporting.

For US readers, the UK increase sits inside a wider push to raise prices in other developed countries as a way to lower them in the United States ^[1][2]. Lilly has not said whether that would produce lower US list prices for its incretin medicines, and no such change has been reported.

What happens next

Ordering in the UK was set to reopen Sept. 1, the same day the higher price takes effect ^[1][2]. Whether supply returns to normal after that, and whether Lilly applies similar increases or limits elsewhere, has not been reported ^[2].